News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
260,773 Results
Type
Article (13900)
Company Profile (294)
Press Release (246579)
Section
Business (79394)
Career Advice (152)
Deals (13195)
Drug Delivery (32)
Drug Development (50303)
Employer Resources (32)
FDA (5679)
Job Trends (5134)
News (144183)
Policy (10018)
Tag
Academia (906)
Alliances (21492)
Alzheimer's disease (736)
Approvals (5653)
Artificial intelligence (63)
Bankruptcy (97)
Best Places to Work (4516)
Biotechnology (242)
Breast cancer (66)
Cancer (695)
Cardiovascular disease (62)
Career advice (132)
CAR-T (56)
Cell therapy (176)
Clinical research (39823)
Collaboration (238)
Compensation (97)
COVID-19 (1005)
C-suite (68)
Cystic fibrosis (66)
Data (793)
Diabetes (73)
Diagnostics (1218)
Earnings (28988)
Events (46895)
Executive appointments (192)
FDA (5971)
Funding (246)
Gene editing (55)
Gene therapy (147)
GLP-1 (300)
Government (1064)
Healthcare (6541)
Infectious disease (1040)
Inflammatory bowel disease (94)
IPO (7184)
Job creations (861)
Job search strategy (127)
Layoffs (184)
Legal (1373)
Lung cancer (111)
Manufacturing (74)
Medical device (2559)
Medtech (2560)
Mergers & acquisitions (6112)
Metabolic disorders (225)
Neuroscience (946)
NextGen Class of 2024 (2003)
Non-profit (848)
Northern California (948)
Obesity (124)
Opinion (91)
Parkinson's disease (61)
Patents (52)
People (25003)
Pharmaceutical (49)
Phase I (14008)
Phase II (18519)
Phase III (11746)
Pipeline (321)
Postmarket research (846)
Preclinical (5926)
Radiopharmaceuticals (205)
Rare diseases (168)
Real estate (1413)
Regulatory (8205)
Research institute (932)
Southern California (865)
Startups (1965)
United States (7617)
Vaccines (159)
Weight loss (76)
Date
Today (66)
Last 7 days (533)
Last 30 days (2305)
Last 365 days (20711)
2024 (19012)
2023 (22427)
2022 (26875)
2021 (27877)
2020 (23435)
2019 (16258)
2018 (11762)
2017 (13759)
2016 (11851)
2015 (14406)
2014 (10426)
2013 (7508)
2012 (7538)
2011 (7634)
2010 (7433)
Location
Africa (146)
Asia (16843)
Australia (2837)
California (2148)
Canada (713)
China (163)
Colorado (81)
Connecticut (85)
Europe (36330)
Florida (229)
Georgia (62)
Illinois (126)
Indiana (54)
Kansas (55)
Maryland (300)
Massachusetts (1707)
Michigan (48)
Minnesota (93)
New Jersey (544)
New York (611)
North Carolina (400)
Northern California (948)
Ohio (79)
Pennsylvania (429)
South America (208)
Southern California (865)
Texas (228)
Washington State (218)
260,773 Results for "stoke therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Genetown
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
Stoke Therapeutics, Inc. today announced that management will present at the following upcoming investor conferences.
June 3, 2024
·
1 min read
Press Releases
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
November 5, 2024
·
11 min read
Business
Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer
Stoke Therapeutics, Inc. today announced the appointment of Thomas (Tommy) Leggett as Chief Financial Officer.
April 29, 2024
·
5 min read
Business
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
Stoke Therapeutics, Inc. today announced the appointment of Jason Hoitt as Chief Commercial Officer.
April 17, 2024
·
6 min read
Business
Stoke Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
Stoke Therapeutics, Inc. reported financial results for the first quarter of 2024 and provided business updates including those related to STK-001, the Company’s proprietary antisense oligonucleotide which is in development by Stoke as the first potential medicine to address the genetic cause of Dravet syndrome.
May 6, 2024
·
13 min read
Genetown
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - June 18, 2024
Stoke Therapeutics, Inc. announced that, effective on June 17, 2024, the company granted stock options to purchase an aggregate of 10,400 shares of common stock to one new employee, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635.
June 18, 2024
·
2 min read
Genetown
Stoke Therapeutics Announces Proposed Public Offering - March 26, 2024
Stoke Therapeutics, Inc. announced a proposed underwritten public offering in which it intends to offer and sell, subject to market and other conditions, up to $75 million of shares of its common stock.
March 26, 2024
·
5 min read
Drug Development
Stoke’s Early-Stage Data for Genetic Epilepsy Drug Sends Stock Skyrocketing
Stoke Therapeutics reported results for Dravet syndrome studies showing clinically meaningful effects, including reductions in convulsive seizure frequency, supporting the potential for disease modification.
March 26, 2024
·
2 min read
·
Kate Goodwin
Genetown
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - May 17, 2024
Stoke Therapeutics, Inc. announced that, effective on May 15, 2024, the company granted stock options of common stock to Thomas Leggett, the Company’s newly-appointed Chief Financial Officer, and four other new employees as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635.
May 17, 2024
·
3 min read
Business
Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the full year ended December 31, 2023.
March 25, 2024
·
7 min read
1 of 26,078
Next
